Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Molecular Insight expands portfolio
January 29, 2007
| A version of this story appeared in
Volume 85, Issue 5
Molecular Insight Pharmaceuticals has licensed Onalta, a radiolabeled peptide for the treatment of pancreatic neuroendocrine and carcinoid tumors, from Novartis. Onalta, which has orphan drug status from FDA, has been studied in Phase I and II clinical trials. Earlier this month, Molecular Insight added another radiotherapeutic to its portfolio by licensing Solazed, Bayer Schering Pharma's small molecule labeled with iodine-131 for the treatment of malignant melanoma. Financial terms of the deals were not disclosed, but both include upfront, milestone, and royalty payments.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter